US Stock MarketDetailed Quotes
GMAB Genmab
- 21.500
- +0.340+1.61%
Close Nov 29 13:00 ET
- 21.500
- 0.0000.00%
Post 17:01 ET
13.66BMarket Cap21.00P/E (TTM)
21.670High21.455Low575.33KVolume21.500Open21.160Pre Close12.38MTurnover0.09%Turnover Ratio23.02P/E (Static)635.14MShares32.88052wk High3.02P/B13.51BFloat Cap20.34052wk Low--Dividend TTM628.37MShs Float49.070Historical High--Div YieldTTM1.02%Amplitude16.240Historical Low21.525Avg Price1Lot Size
About Genmab Company
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Company Profile
SymbolGMAB
Company NameGenmab
Listing DateJul 18, 2019
Issue Price17.75
Founded1998
CEODr. Jan G. J. van de Winkel, PhD
MarketNASDAQ
Employees2204
Securities TypeDR
ADS Ratio10.0 : 1.0
Fiscal Year Ends12-31
AddressCarl Jacobsens Vej 30,Valby
CityCopenhagen
ProvinceCentral Denmark
CountryDenmark
Zip Code2500
Phone45-70-20-27-28
Websitehttp://www.genmab.com
Company Executives
- Name
- Position
- Salary
- Dr. Jan G. J. van de Winkel, PhD
- President and Chief Executive Officer
- 44.30M
- Anthony Mancini
- Executive Vice President and Chief Operating Officer
- 21.80M
- Birgitte Stephensen
- Executive Vice President and Chief Legal Officer
- 10.10M
- Dr. Judith Klimovsky, M.D.
- Executive Vice President and Chief Development Officer
- 21.70M
- Christopher Cozic
- Executive Vice President and Chief People Officer
- 13.20M
- Anthony Pagano
- Executive Vice President and Chief Financial Officer
- 19.60M
- Dr. Martine J. van Vugt, PhD
- Executive Vice President and Chief Strategy Officer
- 8.90M
- Dr. Tahamtan Ahmadi, PhD
- Executive Vice President, Chief Medical Officer and Head of Experimental Medicines
- 19.80M
- Dr. Mijke Zachariasse
- Director, Vice President and Head of Antibody Research Materials
- 1.10M
- Pernille Erenbjerg
- Deputy Chairman of the Board
- 2.10M
- Deirdre P. Connelly
- Chairman of the Board
- 2.80M
- Martin Schultz
- Director, Senior Director and Head of Development Business Partnership and Strategy
- 800.00K
- Anders Gersel Pedersen, M.D.,PhD
- Director
- 1.70M
- Takahiro Hamatani
- Director and Senior Director, Finance Japan
- 800.00K
- Rolf Karl-Heinz Hoffmann
- Independent Director
- 1.50M
- Elizabeth G. O’Farrell
- Independent Director
- 1.90M
- Dr. Paolo Paoletti, M.D.
- Independent Director
- 1.50M
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data